To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

However, even established players have struggled. In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...